Commentary on "Menstrually Related Disorders: Points of Consensus, Debate, and Disagreement" On the other hand, the authors have chosen to publish this and in a format that invites scrutiny. So here goes.
The points of consensus are indeed indisputable, but are they informative? Under "Etiology and Patho physiology," for example, we are told that "the patho physiology of MRDs is likely to be multidimensional and multifactorial, involving various physiologic and biochemical systems." I may be missing something, but as far as I can tell this bit of enlightenment applies to all of the disorders that afflict us, gout to gonorrhea, paranoia to pediculosis. Likewise for "vulnerability of aff ected patients plays a major role in development of specifIc subtypes and symptoms" and "environmental and psychologic factors probably contribute to the de velopment of symptoms as well as determination of their severity." That this stuff was actually written down, and for other people to read, I attribute to the IOSy glow endorsing all ACNP meeting activities.
The proposed name, "Menstrually Related Dis orders," may well sound great to some ears. To me, it seems an unfortunate alliance of nonspecific terms, as doubt that combining the huge number of conditions influenced by climate and age into diagnostic cate gories-climate-related disorders and age-related disorders -adds usefully to our nosology.
On the other hand, some conditions are not just influenced or modified by climate or age; they require a specific climate or age for their expression. Seasonal 0893-133X/93/$6.00
affective disorder and Alzheimer's disease come to mind.
Likewise, it may be worthwhile to identify condi tions the expression of which requires a specifIc phase of the menstrual cycle and to differentiate these condi tions from the innumerable ones for which a phase of the menstrual cycle is a risk or modifying factor.
As far as I know, the only disorder that bears an obligatory relationship to the menstrual cycle is Premen strual syndrome (PMS). It is estimated that 2% to 10% of menstruating women have disabling PMS (Logue and Moos 1986) . The extent to which the clinical and research communities have ignored PMS is all too clear in the contrast between the attention given to PMS and that given to major depression, a condition with a simi lar prevalence.
Among the reasons for the paucity of attention to PMS may be that despite the reasonable presumption that shifts in gonadal steroids account for this condi tion, researchers have been frustrated in their attempts to fmd an endocrine aberration in PMS, and, until re cently, treatments directed toward this condition have been largely unsuccessful. I am dismayed at the possi bility that attention to ill-defIned "Menstrually Related
Disorders" which may not exist will drive PMS further into obscurity.
Failure to uncover the role of gonadal steroids in PMS impugns our current technology more than it does a hormonal basis for the condition. Until we have methods for assessing in vivo the effects of hormones at the molecular level, the role of gonadal steroids in PMS is likely to remain elusive.
Treatment may be less elusive. Recent studies have consistently shown that compounds which potently block serotonin uptake are powerfully effective in the treatment of PMS (Stone et al. 1991; Sundblad et a1. 1992) . Although the studies to date have involved ad-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 ministration of these compounds throughout the men· strual cycle, anecdotal evidence suggests that they may be effective when taken during the premenstrual phase alone (Sundblad et al. 1992) . Thus, these compounds appear to alleviate PMS more rapidly and perhaps via a different mechanism than they alleviate depression. 
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